Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)

NCT06706544 is registered in ClinicalTrials.gov with Bernardino Clavo, MD, PhD as lead sponsor.

NCT NCT06706544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06706544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)
Lead sponsor
Bernardino Clavo, MD, PhD
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 7, 2025
Completion date
March 31, 2030
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn), numbness, paresthesia, tingling